Announcements Trials

Browse Landscape

Phase

Phase 3 2 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 70 Nivolumab 36 Cyclophosphamide 34 Carboplatin 28 Dexamethasone 23 Specimen Handling 22 Paclitaxel 22 Lenalidomide 22 durvalumab 19 Radiotherapy 19 Gemcitabine 19 venetoclax 18 Magnetic Resonance Spectroscopy 18 Doxorubicin 17 Rituximab 16 fludarabine 15 Ipilimumab 15 Bevacizumab 15 Cisplatin 14 Biopsy 14 atezolizumab 13 Etoposide 13 Vincristine 12 Pemetrexed 12 belantamab mafodotin 11 Docetaxel 11 Calcium Dobesilate 11 Azacitidine 11 olaparib 10 Oxaliplatin 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Active not recruiting × zipalertinib × Clear all

NCT04036682 2025-03-13

REZILIENT1

Cullinan Therapeutics Inc.

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡